Table 6 Summary of outcomes
Outcome | Definition | Result |
|---|---|---|
Overall survival | Survival after SRS/HFSRT | 19.4 months (95% CI: 13.2–25.6 months) |
Local control | Absence of new nodular contrast enhancement in the surgical bed compared with the baseline postoperative MRI. | 1 year rate: 72% (95% CI: 60–83%) |
Distant brain control | Absence of new, non-contiguous lesions in either MRI- or CT-follow-up. Leptomeningeal disease was rated as DBF. | 1 year rate: 60% (95% CI: 49–72%), |
Radiation necrosis | Determined based on histologic findings (after surgery) or magnetic resonance spectroscopy (MRS). | 17 (22%) |
Neurological death | Uncontrolled intracranial tumor progress or new/progressive neurological symptoms prior to death | 16 (21%) |
Time to any brain failure | Time after initial SRS/HFSRT to local failure or distant brain failure | 13.9 months (95% CI: 10.7–17.1 months) |
Symptom-free survival | Survival after initial SRS/HFSRT without new or progressive neurological symptoms | 10.2 months (95% CI: 5.7–14.7 months) |
WBRT-free survival | Survival after initial SRS/HFSRT without undergoing WBRT | 17.7 months (95% CI: 13.2–22.3 months) |
Deferment of WBRT | Postponing of WBRT (through regular MRI FU) | MRI FU at 3 months: p = 0.955 ≥1 MRI per 180 days: p = 0.268. |
Time to salvage treatment | Time after initial SRS/HFSRT to first salvage treatment | 15.7 months (range, 2.5–30.2 months) |
Survival after salvage therapy | Survival after first salvage therapy | 11.2 months (range, 0.3–33.7 months) |